The best peptides for kidney health are few, and only one has strong evidence: semaglutide. In the FLOW trial of people with type 2 diabetes and chronic kidney disease, semaglutide 1 mg weekly cut the risk of major kidney events by 24% and cardiovascular death by 29%, and Ozempic is FDA-approved for this use.[2][3] No “kidney support” peptide sold online has been shown to protect the kidneys in humans, and unapproved products carry extra risk when the kidneys are already weak.[11]
This guide puts proven kidney care first, then ranks peptides by evidence. For the wider topic, see our longevity peptides hub.
Evidence at a glance
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Blood pressure control, ACE inhibitor or ARB, SGLT2 inhibitor (standard care) | Human RCTs | SGLT2 inhibitors cut kidney progression or death by 28-39%[6][7] | Approved (not peptides) | — |
| Semaglutide 1 mg (Ozempic) | FDA-approved for this use | 24% fewer major kidney events in FLOW[2] | Approved for CKD in type 2 diabetes[3] | Semaglutide |
| Semaglutide 2.4 mg (Wegovy), no diabetes | Human RCTs | Fewer kidney events in SELECT (1.8% vs 2.2%)[4] | No kidney indication | Semaglutide |
| Tirzepatide | Human RCTs (phase 2, unpublished) | Kidney trial completed 2026[9] | Not approved for CKD | Tirzepatide |
| Epoetin (EPO) | FDA-approved for anemia of CKD | Treats anemia, not kidney decline[10] | Approved for anemia | EPO |
| BPC-157 | No evidence, marketing only | No human kidney trials | Not approved[11] | BPC-157 |
| Thymosin alpha-1 | No evidence for kidneys | No kidney trials | Not approved in the US[11] | Thymosin alpha-1 |
Standard kidney care comes first
Chronic kidney disease (CKD) is managed by controlling its causes and slowing its progress. The international KDIGO guideline covers the core steps: blood pressure control, blocking the renin-angiotensin system with an ACE inhibitor or ARB, an SGLT2 inhibitor for many patients, managing diabetes and heart risk, and avoiding drugs that strain the kidneys.[1]
SGLT2 inhibitors are pills, not peptides, but they have the strongest kidney evidence among newer drugs:
- Dapagliflozin (DAPA-CKD): kidney decline, kidney failure or death fell to 9.2% from 14.5% over 2.4 years.[6]
- Empagliflozin (EMPA-KIDNEY): kidney progression or cardiovascular death fell to 13.1% from 16.9%, with consistent results in people with and without diabetes.[7]
For adults with type 2 diabetes and CKD, the ADA recommends an SGLT2 inhibitor or a GLP-1 drug with proven kidney benefit, regardless of A1C.[8]
Semaglutide: the FLOW trial
FLOW tested semaglutide in 3,533 people with type 2 diabetes and moderate to severe CKD with protein in the urine. To qualify, people needed either an eGFR (a blood-test estimate of kidney filtering) of 50 to 75 with a urine albumin-to-creatinine ratio above 300 mg/g, or an eGFR of 25 to under 50 with a ratio above 100 mg/g. Participants were randomly assigned to semaglutide 1 mg once weekly or placebo, and the trial was funded by the manufacturer. It was stopped early for benefit after a median of 3.4 years:[2]
- Major kidney events (kidney failure, a 50% drop in kidney function, or kidney or cardiovascular death): 24% lower risk (331 vs 410 first events).
- Kidney function decline was slower by 1.16 mL/min/1.73 m² per year.
- Major cardiovascular events were 18% lower, and death from any cause 20% lower.
- Serious adverse events were less common on semaglutide (49.6% vs 53.8%).
Ozempic is now approved to reduce the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and CKD.[3] Our Ozempic kidney disease guide goes deeper.
How it is dosed. Per the label, Ozempic starts at 0.25 mg once weekly for 4 weeks, then rises to 0.5 mg, with further steps to 1 mg and 2 mg if needed, each after at least 4 weeks. The label recommends no dose adjustment for reduced kidney function, because kidney impairment, including kidney failure, did not meaningfully change semaglutide levels in the body.[3] Your clinician sets the dose.
Without diabetes. In SELECT, adults with heart disease and overweight or obesity but no diabetes had fewer kidney events on semaglutide 2.4 mg (1.8% vs 2.2%).[4] A 2026 pooled analysis of SELECT, FLOW and SOUL, covering 30,787 people, found a 16% lower risk of the main kidney composite with semaglutide.[5] That analysis was funded by the manufacturer.
Tirzepatide and other GLP-1 drugs
Tirzepatide is not approved for kidney disease. TREASURE-CKD, a phase 2 trial in 134 people with overweight or obesity and CKD, was completed in July 2026.[9] We did not find peer-reviewed results as of October 2026. For heart and kidney effects of the whole drug class, see our GLP-1 heart outcomes guide.
EPO: treats anemia, not kidney damage
Healthy kidneys make erythropoietin (EPO), the hormone that signals the bone marrow to make red blood cells. In CKD, levels fall and anemia is common. Lab-made versions, called erythropoiesis-stimulating agents (ESAs), are glycoproteins rather than small peptides. The 2026 KDIGO anemia guideline recommends correcting other causes of anemia first, using an ESA as first-line drug treatment when needed, and keeping hemoglobin below 11.5 g/dL during maintenance.[10] ESAs do not slow kidney damage, and misuse is dangerous.
Why unproven peptides are a special risk in kidney disease
Peptides marketed for “kidney support” or “detox,” such as BPC-157, have no human kidney trials. FDA says it has identified little or no safety information for BPC-157 and notes concerns about impurities and immune reactions. It also lists thymosin alpha-1 and other wellness peptides among bulk substances whose compounding nominations raised safety concerns.[11]
These risks matter more with weak kidneys:
- Clearance. Many drugs and their breakdown products leave the body through the kidneys, so doses that are tolerated with normal kidneys may build up.
- Unknown contents. Research-grade products are not checked for purity or dose. Our counterfeit peptides guide explains common problems.
- Dehydration. Even approved GLP-1 drugs can cause acute kidney injury, sometimes needing dialysis, mostly after vomiting or diarrhea led to dehydration.[3]
For context on how lab and animal findings often fail in people, see why animal peptide studies don’t translate. Related longevity reading: mitochondrial peptides research and thymosin alpha-1 vs LL-37.
Questions to ask your nephrologist
- What stage is my CKD, and what is my urine albumin level?
- Am I on an ACE inhibitor or ARB and an SGLT2 inhibitor, if appropriate?
- Would semaglutide help me, and how will we watch my kidney function?
- Which supplements or peptides should I avoid?
- What should I do if I get vomiting or diarrhea and cannot keep fluids down?
